PTC-209

PTC-209 is a specific BMI-1 inhibitor with an IC50 of 0.5 μM in HEK293T cell line. PTC-209 irreversibly impairs colorectal cancer-initiating cells (CICs) . PTC-209 shows potent anti-myeloma activity and impairs the tumor microenvironment[1][2].

Product Specifications

CAS Number

[315704-66-6]

UNSPSC

12352005

Hazard Statement

H315, H319, H320

Target

Autophagy; BMI1

Type

Reference compound

Related Pathways

Autophagy; Stem Cell/Wnt

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/PTC-209.html

Purity

99.76

Solubility

DMSO : ≥ 32 mg/mL

Smiles

CC1=C(C2=CSC(NC3=C(Br)C=C(OC)C=C3Br)=N2)N4C=CC=NC4=N1

Molecular Formula

C17H13Br2N5OS

Molecular Weight

495.19

Precautions

H315, H319, H320

References & Citations

[1]Kreso A, et al. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med. 2014 Jan;20 (1) :29-36.|[2]Chen D, et al. Targeting BMI1+ Cancer Stem Cells Overcomes Chemoresistance and Inhibits Metastases in Squamous Cell Carcinoma. Cell Stem Cell. 2017 May 4;20 (5) :621-634.e6.|[3]Sulaiman S, et al. PTC-209 Anti-Cancer Effects Involved the Inhibition of STAT3 Phosphorylation. Front Pharmacol. 2019;10:1199. Published 2019 Oct 21.